BackKyntra Bio Overview

Kyntra Bio Current Cash

Latest current cash for KYNB: $51M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$50.64M
↑ 116.73% YoYΔ $27.28M vs prior year quarter

Peer trimmed avg / median

Loading

Kyntra Bio Current Cash History

Loading

Kyntra Bio vs. peers: Current Cash Comparison

Loading

Kyntra Bio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Kyntra Bio (KYNB) FAQ

As of the most recent data (June 2026), KYNB shows a current cash of $51M. That compares with $23M in the prior-year period — up 116.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KYNB's current cash is now $51M (was $23M) — a 116.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Kyntra Bio is outperforming or lagging.

Tracking KYNB's current cash over time shows whether Kyntra Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $51M That compares with $23M in the prior-year period — up 116.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Kyntra Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $51M) with ownership activity and broader fundamentals.

Kyntra Bio's current cash is $51M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.